CLDX · Celldex Therapeutics Inc
United States · RS rating 37 · As of 2026-11-03
| Price | 29.71 USD |
|---|---|
| 1-day change | +2.3% |
| RS rating (overall / 1M / 3M / 12M) | 37 / 37 / 23 / 61 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 26 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -20.8% |
| Sales growth Q/Q | -87.6% |
| Distance from 52-week high | +33.8% |
| Market cap (USD) | $2.6B |